HomeRGLS • NASDAQ
add
Regulus Therapeutics Inc
Previous close
$1.40
Day range
$1.37 - $1.48
Year range
$1.08 - $3.79
Market cap
96.29M USD
Avg Volume
407.53K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 14.19M | 81.62% |
Net income | -14.06M | -79.73% |
Net profit margin | — | — |
Earnings per share | -0.21 | 47.50% |
EBITDA | -15.12M | -87.38% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 87.31M | 183.64% |
Total assets | 93.76M | 148.40% |
Total liabilities | 6.96M | -26.67% |
Total equity | 86.80M | — |
Shares outstanding | 65.50M | — |
Price to book | 1.05 | — |
Return on assets | -38.43% | — |
Return on capital | -40.53% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | -14.06M | -79.73% |
Cash from operations | -9.45M | -50.53% |
Cash from investing | 18.64M | 442.72% |
Cash from financing | 56.00K | -80.49% |
Net change in cash | 9.25M | 180.94% |
Free cash flow | -4.32M | -55.64% |
About
Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals. Wikipedia
Founded
Sep 2007
Website
Employees
32
